Omeros Announces Completion of IgA Nephropathy Cohort in OMS721 Phase 2 Clinical Trial

Omeros Announces Completion of IgA Nephropathy Cohort in OMS721 Phase 2 Clinical Trial


All patients in the cohort have now completed the OMS721 treatment and follow-up periods. The additional Phase 2 results in IgA nephropathy patients expand on the data reported earlier this year and further demonstrate marked and statistically significant improvement in urine protein levels .



from Biotech News